Subscribe To
Veracyte (vcyt) reports q4 loss, tops revenue estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the qua...
February 22, 2023, 7:34 pm
Incyte (incy) reports positive long-term data from hs study
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open...
February 13, 2023, 1:33 pm
Vaxcyte to present at the svb securities global biopharma conference
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
February 7, 2023, 9:05 pm
Incyte corporation (incy) q4 2022 earnings call transcript
Incyte Corporation (NASDAQ:INCY ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company ...
February 7, 2023, 12:11 pm
Incyte's (incy) q4 earnings, revenues top on jakafi, opzelura
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recentl...
February 7, 2023, 12:03 pm
Incyte (incy) tops q4 earnings and revenue estimates
Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarte...
February 7, 2023, 9:47 am
Iovance: capturing a lucrative market
Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. The recent Proleukin ...
February 1, 2023, 6:33 pm
3 reasons why growth investors shouldn't overlook incyte (incy)
Incyte (INCY) could produce exceptional returns because of its solid growth attributes....
February 1, 2023, 2:18 pm
Incyte (incy) is a great momentum stock: should you buy?
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out....
January 27, 2023, 1:33 pm
Better long-term buy in 2023: exact sciences or veracyte?
As cancer screenings are becoming covered more often, both companies stand to gain....
January 24, 2023, 10:23 am
Incyte: opzelura is the main growth driver
Opzelura's approval in vitiligo in the USA is the main growth driver. Next driver is Opzelura's approval for the vitiligo treatment in Europe. The iss...
January 24, 2023, 9:24 am
Incyte: making hay while the sun shines
It is useful to understand the financial implications for Incyte with its major product, JAKAFI, facing...
January 22, 2023, 7:48 am
Incyte (incy) up 7% in a year: will the momentum continue?
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to cont...
January 17, 2023, 11:18 am
Maxcyte signs strategic platform license with catamaran bio to support its car-nk cell therapy programs
Maxcyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILW...
January 3, 2023, 9:05 pm
H-cyte completes acquisition of skindisc™ regenerative tissue kit from scion solutions, llc
Wound Healing and Limb Salvage Technology Added to Growing Asset PortfolioCompany’s Second Completed Transaction in Four Months TAMPA, Fla., Dec. 29...
December 29, 2022, 12:00 pm
Maxcyte, inc. (mxct) loses 18.8% in 4 weeks, here's why a trend reversal may be around the corner
Maxcyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have...
December 21, 2022, 11:17 am
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics compa...
December 16, 2022, 8:19 am
Incyte to present at upcoming investor conferences
WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) announced today that it will present at the f...
December 15, 2022, 8:00 am
5 most cheapest stocks in the healthcare sector: bio-techne, mirati therapeutics and more - corcept therapeutics (nasdaq:cort), cytek biosciences (nasdaq:ctkb)
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies....
December 15, 2022, 7:19 am
What makes veracyte (vcyt) a new buy stock
Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the compa...
December 12, 2022, 1:32 pm